

## Review Article

Indian J Med Res 152, December 2020, pp 541-552  
DOI: 10.4103/ijmr.IJMR\_1450\_18



# Therapeutic uses of post-partum tissue-derived mesenchymal stromal cell secretome

Vindya Lankika Udalamaththa<sup>1</sup>, Athula Kaluarachchi<sup>2</sup>, Sumedha Wijeratne<sup>3</sup> & Preethi Vidya Udagama<sup>1</sup>

<sup>1</sup>Department of Zoology & Environment Sciences, Faculty of Science, <sup>2</sup>Department of Obstetrics & Gynaecology, Faculty of Medicine, University of Colombo & <sup>3</sup>Vindana Reproductive Health Centre, Colombo, Sri Lanka

Received August 3, 2018

**Human post-partum tissue mesenchymal stromal cells (hPPT-MSCs) are widely used in research to investigate their differentiation capabilities and therapeutic effects as potential agents in cell-based therapy. This is ascribed to the advantages offered by the use of MSCs isolated from hPPT over other MSC sources. A paradigm shift in related research is evident that focuses on the secretome of the human MSCs (hMSCs), as therapeutic effects of hMSCs are attributed more so to their secreted growth factors, cytokines and chemokines and to the extracellular vesicles (EVs), all of which are components of the hMSC secretome. Positive therapeutic effects of the hPPT-MSC secretome have been demonstrated in diseases related to skin, kidney, heart, nervous system, cartilage and bones, that have aided fast recovery by replacing damaged, non-functional tissues, via differentiating and regenerating cells. Although certain limitations such as short half-life of the secretome components and irregular secreting patterns exist in secretome therapy, these issues are successfully addressed with the use of cutting-edge technologies such as genome editing and recombinant cytokine treatment. If the current limitations can be successfully overcome, the hPPT-MSC secretome including its EVs may be developed into a cost-effective therapeutic agent amenable to be used against a wide range of diseases/disorders.**

**Key words** Extracellular vesicles - human mesenchymal stromal cell secretome - post-partum tissue - stem cell therapy

## Introduction

Stem cell (SC) research has brought regenerative medicine to the forefront of cell-based clinical research and therapy due to promising outcomes. SC research has produced cells, tissues and whole organ-like structures *in vitro* using SCs to replace damaged or non-functional tissues or organs by transplantation<sup>1</sup>. Diseases such as autism<sup>2</sup> and muscular dystrophies<sup>3</sup> which are labelled as incurable have gained promising results using SC therapy.

Pluripotent embryonic SCs (ESCs) isolated from the blastocyst stage of embryos have ethical concerns than the multipotent adult SCs which are isolated from the bone marrow, brain and heart tissue; post-partum tissue (PPT) such as umbilical cord (UC), UC blood (UCB), amniotic membrane (AM) and placenta and surgical waste such as deciduous teeth pulp and adipose tissue (AD)<sup>4</sup>. As ESC sources are the stored embryos at assisted reproductive centres, varying ethical issues dependent on the country of use, in addition to their tumourigenic capacity have limited the use of ESCs in

research<sup>5</sup>. Induced pluripotent SCs, adult cells which are reprogrammed to function as embryonic-like SCs, have also shown great potential in therapeutics<sup>6</sup>. Among the different types of adult SCs, bone marrow SCs (BM-SCs) have widely been used in research. With the ability of establishing SCs from biological and surgical waste, SC research has flourished mainly due to the minimum ethical considerations associated with the use of such waste starting material<sup>7</sup>. High availability<sup>8</sup>, absence of tumourigenicity and favourable immune-privileged effects<sup>9</sup> are other reasons for the increased use of SCs in biological waste material to fulfil the demand of the ever-rising numbers of therapy trials. Mesenchymal stromal cells (MSCs) and haematopoietic SCs (HSCs) derived from PPT are such adult SC categories that are in the initial stages of clinical trials. As at November 2020, the US National Institutes of Health SC registry lists 5685 SC-related clinical trials, of which 86 are related to HSCs derived from cord blood and 58 trials related to MSCs from other PPTs<sup>10</sup>.

With the use of relatively easy isolation methods, low rejection rates, high availability and wide differentiation potential, PPT-SCs have gained attention in SC research. hMSCs can be isolated from all PPTs using either digestion or explant methods. UCB provides a source to isolate HSCs by selecting CD34+ cells and expanding them in a suitable medium supplemented with selected cytokines as non-adherent cultures<sup>11</sup> or else UCB can be used to isolate MSCs by expanding mononuclear cells (MNCs) as adherent cultures<sup>12</sup>. UCB-hMSC showed significantly higher proliferation, clonality and/or significantly lower expression of p53, p21 and p16, well known markers of senescence, compared to BM and AD hMSCs<sup>11</sup>. However, successful isolation of hMSCs from UCB is believed to depend on the time between collection and isolation, the net volume of blood and the MNC count; hence, the isolation process itself becomes laborious and time-consuming, resulting in low yields of hMSCs<sup>13</sup>. Due to such difficulties confronted, as well as contemplation by parents on storing UCB in blood banks for future use of their child, the use of other types of PPT are considered. Although their self-renewal capacity when compared with other hMSCs was not significantly different, placenta-hMSC showed high proliferative capacity and better growth characteristics than bone marrow, adipose-derived and UCB-hMSCs<sup>11</sup>. Expression of stemness markers was not significantly different between these hMSCs, making UCB and placenta-hMSCs potential candidates

for research akin to bone marrow- or adipose-derived hMSCs<sup>11</sup>. Although 5-50 per cent of SC marker-positive cells reside within the population of amniotic epithelial cells, a mere 0.01-0.1 per cent SCs are present within the other residing tissue types<sup>14</sup>, making the AM a rich source of SCs compared to somatic tissues. Human AM-MSCs, UC-MSCs and UCB-MSCs also demonstrate immunosuppressive properties<sup>15-17</sup>. In an *in vitro* study, human placenta-MSCs have shown a significantly higher ability of immunosuppression compared to human UC-MSCs<sup>18</sup>.

It is believed that most of the therapeutic effects are due to different bioactive molecules such as growth factors, cytokines, chemokines and angiogenic factors that are secreted by SCs which are collectively known as the 'stem cell secretome', and all these molecules have been thoroughly investigated<sup>19</sup>. It is reported that the UC-MSC secretome is significantly different from the bone marrow- and adipose-derived SC secretomes<sup>20</sup>. This article reviews the therapeutic effects of the UC-derived mesenchymal SC secretome and highlights the pros and cons of its applications, compared to other SC secretomes.

### Composition of the PPT-MSC secretome

A typical hMSC secretome is known to contain growth factors, cytokines, extracellular vesicles, lipid mediators, extracellular membrane proteases and hormones<sup>21</sup>, causing differential effects on the treated cells.

### Growth factors and cytokines

Composition of the Wharton's jelly (WJ) hMSC secretome was investigated using homonuclear magnetic resonance and multiplexing laser bead technology in a study, where it was discovered that compared to unconditioned medium, conditioned medium consisted of increased levels of transforming growth factor- $\beta$ 1, epidermal growth factor (EGF), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), platelet-derived growth factor-AA and vascular endothelial growth factor (VEGF) as well as a range of cytokines such as interleukin (IL)-12p70, interferon-gamma, IL-17A and IL-10<sup>22</sup>. VEGF and fibroblast growth factor (FGF) possess cardioprotective and cardioregenerative effects<sup>23</sup>; the inclusion of VEGF in the UC-hMSC secretome may lead the secretome to manifest such properties. Wound healing capacity of the secretome may be attributed to the presence of IL-6, IL-8 and MCP-1

that enhance monocyte migration into injured sites, thereby suggesting the migration of other cell types such as fibroblasts into the wound sites with the help of mentioned cytokines when treated with the secretome<sup>24</sup>. There is a wide range of proliferative and anti-apoptotic growth factors, immunomodulatory, immunosuppressive cytokines and chemokines listed as constituents of the secretome<sup>22</sup>, which may well surmount to different activities and effects exerted by the secretome.

### ***Extracellular vesicles (EVs)***

Other than the soluble factors of the secretome, extracellular vesicle (EV) is an additional distinct component with a size range of 80 nm to 1  $\mu\text{m}$ <sup>25</sup> and categorized into three subtypes: exosomes, microvesicles and apoptotic bodies<sup>26</sup>. Components such as proteins, lipids and functional genetic material [DNA, microRNA (mRNA) and fragmented DNA] present in these vesicles are transferred into other target cells aiding regulation requirements for therapeutic procedures in SC therapy<sup>27</sup>. UC-MSC-derived nanovesicles have been reported to confer therapeutic effects on skin burn rat models by accelerating skin damage repair via Wnt-signalling pathway<sup>28</sup> and murine models on hypoxic pulmonary hypertension by exerting lung protection and reducing pulmonary hypertension via STAT-3-mediated signalling pathway<sup>29</sup>. Both these studies report that the exosome-carrying EVs are responsible for the therapeutic effects, suggesting mRNA-mediated cell signalling.

Large-scale manufacturing of EVs is required to be used in therapeutic platforms. Different culture systems with varying parameters such as thermal stress, hypoxia, radiation, increase of intracellular calcium levels and sulphhydryl-blocking agents have been identified as potential factors which enhance the EV-secreting ability<sup>30</sup>.

### **Significance of the hPPT-MSC secretome**

Of the MSC secretomes, the UC-MSC secretome has proven to be significantly different from BM-MSC and adipose-derived MSC secretomes<sup>31</sup>. UC-MSCs show significantly reduced synthesis of important proangiogenic factors but increased secretion of angiogenic growth factors and chemokines when compared to BM-MSCs and AD-MSCs<sup>32-34</sup>. UC-MSCs have also demonstrated significantly higher increased secretion of neurotrophic factors<sup>35</sup>, important cytokines and haematopoietic growth factors than the BM-MSC

and AD-MSC secretomes<sup>36</sup>, pointing towards the potential benefits of therapy specific to the UC-MSC secretome. A study comparing the effects of BM-MSC and WJ-MSC secretomes on neural differentiation demonstrated different temporal profiles regarding stimulation of neurite outgrowth and the gene expression of neuronal markers<sup>37</sup>. Although proteomic-based mass spectrometry has shown differences of protein profiles among the BM, AD and UC-MSC secretomes, it also confirmed that the UC-MSC secretome is a potential candidate for neuroregenerative research as much as the other two secretomes<sup>31</sup>. UC-MSCs cultured using post-partum waste and the resultant secretome obtained with ease, together with minimum ethical considerations, will augment its value in cell-free therapeutic procedures. The following subsections highlight research in which UC-MSC secretome was investigated in different therapeutic procedures against a wide range of diseases.

### **Therapeutic effects of hPPT-MSC secretome**

#### ***Anti-ageing and other skin repair therapies***

Skin is the main target of most cosmetic products. Anti-ageing and skin tone-lightening products are enormously marketed by pharmaceutical and cosmetic companies. Importance of using naturally derived stimulants or inhibitors for cosmetic purposes is highly recommended as skin is a very sensitive organ and the consumers are extremely cautious about the side effects and toxicity of such products. Pharmaceutical companies are focusing on naturally derived components to reduce their production costs which may target a wide array of the population regardless of their economic status.

Late recovery of skin wounds caused by different injuries is also a growing concern as it decreases the quality of life of the patient by scar formation and increased risk of infection<sup>38</sup>. Diabetic wounds result only in 50 per cent short-term recovery, even under high standard treatment methods<sup>39</sup>, which suggests that the current therapeutic methods require change. Conversely, burn wounds also require critical care to stabilize and functionally recover the patients<sup>40</sup>. Table I lists the research where PPT-derived SC-conditioned medium was used to manifest anti-ageing and anti-melanogenesis effects, as well as to successfully recover wounds of different origin, *i.e.*, diabetic wounds and burn wounds. Type of animal model or human cell lines used for these

**Table I.** Use of human post-partum tissue mesenchymal stromal cells secretome in treating diseases related to skin

Type of secretome/CM	Disease	Animal models or cell type	Outcome	Possible mechanisms	References
WJ-hMSC	Ageing effects	UVA irradiated human dermal fibroblasts ( <i>in vitro</i> )	Increased proliferation, migration rates and TGF- $\beta$ signalling <sup>41</sup>	Increased cell migration via TGF- $\beta$ smad signalling pathway	Sánchez-A, 2005 <sup>42</sup>
UC-hMSC	Ageing effects	Human dermal fibroblasts in high glucose induced diabetic microenvironment ( <i>in vitro</i> )	Decreased ROS production and senescence	Antioxidant and anti-ageing effects through downregulating expression of senescence-related genes	Li <i>et al</i> , 2017 <sup>43</sup>
UC-hMSC	Diabetic wounds	Delayed wound healing mouse models (diabetic wounds) ( <i>in vivo</i> )	Significantly higher wound closure rates, capillary densities and PDGF- $\beta$ , KGF, VEGF expression levels	By increasing expression of important growth factors related to dermal healing	Shrestha <i>et al</i> , 2013 <sup>44</sup>
UC-hMSC	Burn wounds	Rats with induced burn wounds ( <i>in vivo</i> )	Acceleration of wound closure. High density of collagen fibers, increased numbers of fibroblasts and blood vessels	bFGF-mediated cell regeneration	Padeta <i>et al</i> , 2017 <sup>45</sup>
Hypoxic AF-hMSC	Skin wounds	Rats with induced wounds ( <i>in vivo</i> ) and human skin fibroblasts ( <i>in vitro</i> )	Enhanced proliferation and migration of human dermal fibroblasts <i>in vitro</i> and wound healing in rat model	Via TGF- $\beta$ /SMAD2 and PI3K-PKB/Akt pathways	Jun <i>et al</i> , 2014 <sup>46</sup>
UC-hMSC	Wound healing	Human umbilical vein endothelial cells ( <i>in vitro</i> ) and rats with induced wounds ( <i>in vivo</i> )	Decreased inflammation at initial stage, cell migration and angiogenesis stimulation <i>in vitro</i> and <i>in vivo</i>	-	Kusindarta <i>et al</i> , 2016 <sup>47</sup>
UC-hMSC infected with Wnt7a-expressing virus	Cutaneous wounds	Mice with full thickness skin injury ( <i>in vivo</i> )	Stimulation of wound closure and regeneration of hair follicles	Via activating fibroblasts enhanced secretory expression of ECM components which promotes keratinocyte migration and reepidermalization. Also enhances crosstalk between cells in complex wound microenvironment	Dong <i>et al</i> , 2017 <sup>48</sup>
UCB-hMSC	Melanin synthesis (cosmetic use)	Hyperpigmented melanoma cells and normal human epidermal melanocytes ( <i>in vitro</i> )	Inhibition of melanogenesis	Via degradation of MITF expression via the ERK signalling pathway	Kim <i>et al</i> , 2015 <sup>49</sup>
UCB-hMSC	Skin ageing	Dermal fibroblasts and women with wrinkles	Stimulate growth and production of HDFs by ECM, promoted antiwrinkle effect and dermal density was significantly increased in women	GDF-11 aided in promoting skin rejuvenation via upturned growth and ECM production of human dermal fibroblasts	Kim <i>et al</i> , 2018 <sup>50</sup>

Contd...



Type of secretome/CM	Disease	Animal models or cell type	Outcome	Possible mechanisms	References
WJ-hMSC	Radioactive dermatitis	UVEC and rat models with radiation induced skin wounds	Stimulated proliferation of UVECs, sebaceous glands were regenerated and stimulated angiogenesis and wound healing <i>in vivo</i>	-	Sun <i>et al</i> , 2019 <sup>51</sup>

CM, conditioned medium; ECM, extracellular matrix; MITF, microphthalmia-associated transcription factor; HDFs, human dermal fibroblasts; ECM, extracellular matrix; GDF-11, growth differentiation factor-11; UVEC, umbilical vein endothelial cells; TGF- $\beta$ , transforming growth factor beta; ROS, reactive oxygen species; hMSC, human mesenchymal stromal cells; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; KGF, keratinocyte growth factor; BFGF, basic fibroblast growth factor; PI3K, phosphoinositol-3-kinase; WJ, Wharton's jelly; UCB, umbilical cord blood; UC, umbilical cord; AF, amniotic fluid; ERK, extracellular signal-regulated kinase; UVA, ultraviolet A; PKB, protein kinase B

experiments, the outcomes and plausible underlying mechanisms of each report are also summarized in Table I.

### **Anticancer therapy and other cancer-related therapy**

As projected in 2012, by 2030, of the global cancer burden, new cancer cases will account to 21.7 million and cancer deaths are calculated around 13 million<sup>52</sup>. Despite cancer screening programmes for early detection, public awareness programmes and treatment methods linked with novel technological advances, cancer had struck globally with no impact of the economic status of the countries<sup>53</sup>. Effective treatment is a major component of a balanced approach to cancer<sup>54</sup>, where anticancer drugs and other methods to eliminate cancer are investigated to match the ever-rising numbers of cancer patients and different cancer types. Of the small molecules approved as anti-cancer drugs from 1940s to 2012, 48.5 per cent were reported to be natural products or derivatives of natural products<sup>54</sup>. However, cytokines, growth factors and other compounds extracted from human biological material appear to be equally effective in anticancer therapy; hence, the hMSC secretome was investigated for its anticancer potential. Table II elaborates the use of human PPT (hPPT)-MSC secretome on anticancer-related therapy for human laryngeal carcinoma, lung cancers, leukaemia, hepatic and cervical cancers investigated in *in vitro* studies using human cancer cell lines. The outcomes were apoptosis, inhibition of drug resistant effects, antiproliferative and cell viability effects; the associated mechanisms are listed in Table II. In addition, Zimmerlin *et al*<sup>61</sup>, reported on many MSC-secreted factors effective on a wide range of cancers including non-specified paracrine factors secreted from UC-MSCs.

### **Use of hPPT-MSC secretome in therapeutic procedures against various other diseases**

*In vitro* differentiated cells have the advantage of aiding fast recovery of the patient, rather than the time-consuming method of transplanting undifferentiated SCs which would differentiate and then replace the non-functional or injured tissue. Procedures to differentiate SCs into a variety of mature cell types *in vitro* and *in vivo* under different stimulated conditions such as by adding synthetic and natural compounds have been investigated; and, the hMSC secretome rich in various growth factors and cytokines has also been explored. In 2014, a phase 1 clinical trial was set up with 20 patients, to investigate the

**Table II.** Use of human post-partum tissue mesenchymal stromal cells secretome on anticancer therapy

Type of secretome/CM	Type of cancer	Human cell line used	Outcome	Possible mechanisms	References
WJ-hMSC	Human laryngeal carcinoma	Hep-2 cell line ( <i>in vitro</i> )	Caused apoptosis in Hep-2 cells	Via increase p53 and decrease of Bcl-2	Elias <i>et al</i> , 2016 <sup>55</sup>
WJ-hMSC	Lung cancer	A549 lung cancer cells ( <i>in vitro</i> )	Drug resistant effects inhibited	-	Hendijani <i>et al</i> , 2015 <sup>56</sup>
WJ-hMSC	Leukaemia cells	K562 leukaemia cells	Significant antiproliferative effects	-	Hendijani <i>et al</i> , 2014 <sup>57</sup>
AM-hMSC	Hepatic carcinoma	HepG2 cell line ( <i>in vitro</i> )	Decreased cell proliferation and cell viability	Via increased expression of p53, p21 and Caspase 3 (proapoptotic mRNA) and diminished expression of Ki-67 (cell proliferation marker)	Riedel <i>et al</i> , 2017 <sup>58</sup>
UCB-hMSC	Cervical cancer	HeLa cell line ( <i>in vitro</i> )	Significantly induced apoptosis	Via mitochondrial apoptotic pathway	Sandra <i>et al</i> , 2014 <sup>59</sup>
WJ-MSC	Breast Cancer	MCF-7 cell line ( <i>in vitro</i> )	Induced apoptosis	Not specified	Mirabdollahi <i>et al</i> , 2019 <sup>60</sup>

CM, conditioned medium; WJ, Wharton's jelly; hMSC, human mesenchymal stromal cells; AM, amniotic membrane; UCB, umbilical cord blood; mRNA, microRNA


effect of microvesicles derived from UCB-MSCs, to decrease the inflammatory state and enhance the  $\beta$ -cell mass as well as the glycaemic control<sup>62</sup>. Two recent studies have also been registered on NIH clinical trials, US data base, on uses of secretome of adipose derived MSC for the treatment of Osteoarthritis and for Articular Regeneration and using hypoxia-MSC secretome to treat COVID-19 patients<sup>63,64</sup>. Table III summarizes such research where the secretome was used in cell differentiation and cell protection protocols for therapeutic applications in cartilage disorders, Parkinson's disease, ischaemia, cardiotoxicity, acute myocardial infarction, pulmonary artery hypertension, chronic renal disease and skeletal muscle atrophy.

In addition, HSCs were also reported to increase their proliferation rates due to paracrine factors secreted by WJ-hMSCs such as IL1a, IL-6, IL-7, IL-8 cytokines, hyaluronic acid, cell adhesion molecules, cadherins and growth factors [stem cell factor and hepatocyte growth factor (HGF)] which are secreted in high amounts than BM-hMSC<sup>36,77</sup>. Figure presents the gist of the review in a nutshell.

### Limitations and the way forward with the hPPT-MSC secretome

Although many potential beneficial therapeutic advantages of the PPT-MSC secretome are apparent, yet the most important issue involved is controlling the MSCs to continuously secrete the required factors in adequate amounts, because the secretion of secretome factors varies due to the state of the cells and the passage number of the cell line<sup>78,79</sup>. In therapeutic procedures where hPPT-MSCs are transplanted, the short half-life of the secreted factors, such as HGF which only remains viable for 3-5 min, raises another concern; administering continuous doses of such secreted stimulants with extremely short half-lives to patients is required for positive therapeutic effects<sup>80</sup>. Solution to this problem was provided with the use of genome-editing technologies, where the genome of UCB-hMSCs was edited to render the cells continuously secrete HGF, but in an induced manner<sup>76</sup>. Furthermore, treatment of hMSCs with different cytokine cocktails modified the hMSC secretome by directing hMSCs to secrete specific required factors to render considerable therapeutic effects against, for example, liver inflammation by improving the immunomodulatory capacity<sup>81</sup>.

Existing literature supporting the presence of the therapeutic effects of EVs is another future aspect of



**Figure.** Human post-partum tissue mesenchymal stromal cells secrete growth factors, chemokines, cytokines and extracellular vesicles which form the components of its secretome. These secretome components manifest different therapeutic effects. List of advantages and disadvantages of the therapeutic use of human post-partum tissue mesenchymal stromal cell secretome over current cell therapy methods is provided.

the hMSC secretome to be examined. Purification of these EVs from the secretome is important as a study demonstrated that the purity of EVs secreted by UC-hMSCs is a limiting factor for their immunosuppressive effects<sup>82</sup>. Provision of solutions to issues related to the therapeutic uses of MSC secretome by means of gene editing, cytokine therapy and extrapurification procedures may however, lead to increased charges of such therapeutics, rendering these unavailable for the developing world. This single reason could mar the beneficial use of the hMSC secretome or its secreted components in therapy; hence, when producing at the commercial scale, it is crucial to adapt to procedures where the current limitations will be overcome in a cost-effective manner. Furthermore, the mRNAs transported by exosomes had been reported to be mediators of cancer communication and also associated with a number of neurodegeneration disorders; hence, further analysis of these derivatives should be done before clinical applications<sup>83</sup>. Use of standardized herbal extracts as an alternative may be an inexpensive option as a range of herbal extracts have shown proliferation and differentiation abilities when used on SCs<sup>7</sup>, suggestive of induced changes to the secretome. Countries rich in biodiversity and

traditional medicine knowledge can actively contribute to achieve this goal, collaborating with countries which possess cutting edge technological advances, so that ‘induced secretome therapy’ may be affordable globally.

## Conclusions

The properties of the hPPT-MSC secretome, provided through a strong and growing body of evidence, bear ample testimony to the potential therapeutic usage of it. However, extensive clinical trials are warranted to reinforce facts and figures obtained by *in vitro* and *in vivo* animal studies. Limiting factors of the hPPT-MSC secretome in therapeutic usage can be surmounted by strategies with the help of cutting-edge technologies. However, there is a risk in decreasing the cost-effectiveness of the proposed secretome therapy by the use of such novel technological advances using expensive reagents and equipment; hence, as an alternative, standardized herbal extracts may be used which are naturally available, cheaper, non-toxic and scientifically proven and are effective on hMSCs that will render these cells and their secretome therapeutically feasible, by inducing hMSCs to secrete its components selectively,

**Table III.** Use of human post-partum tissue mesenchymal stromal cells secretome in cell differentiation, cell protection and various other disease therapeutics

Type of secretome/CM	Therapeutic application	Animal models or cell type	Outcome	Possible mechanisms	References
Thrombospondin-2 secreted by UCB-hMSC	Cartilage disorders	Chondro progenitor cells and rabbits with full-thickness osteochondral defects	Increased chondrogenic effects	Through signalling pathways such as PKC $\alpha$ , ERK, p38/MAPK and notch	Jeong <i>et al</i> , 2013 <sup>65</sup>
WJ-hMSC	Cartilage disorders	Chondrocytes	Increased expression of cartilage specific genes	Via significantly enhanced expression of collagen type II, Sox-9, aggrecan and COMP genes	Hassan Farnian <i>et al</i> , 2017 <sup>66</sup>
Amniotic epithelial cells	Dopaminergic neuron to treat Parkinson's disease	UCB-hMSC	Differentiation into dopaminergic neuron-like cells	Through neurotrophic factor BDNF and NGF, derived in brain	Yang <i>et al</i> , 2013 <sup>67</sup>
UCB-hMSC	Protection of ischaemic cardiomyocytes	Murine HL-1 cardiomyocytes subjected to stimulated ischaemia	Decreased number of dead cells and increased viability	Via enhancement of Akt, ERK and transcription factor STAT3 (cell survival promoting kinases) phosphorylation	Bader <i>et al</i> , 2013 <sup>68</sup>
Amniotic fluid SC	Protection from cardiotoxicity	H9c2 cardio myoblasts and primary mouse neonatal ventricular cardiomyocytes	Blockage doxorubicin induced cardiotoxicity senescence and apoptosis	Via activation of PI3K/Akt signalling cascade and upregulation of its related genes	Lazzarini <i>et al</i> , 2016 <sup>69</sup>
AM-hMSCs Injecting CM into infarcted rat hearts	Acute myocardial infarction	Rat models with heart infarcts	Infarct size limitation, reduced cardiomyocyte apoptosis, ventricular remodeling and increased capillary formation	Via activation of prosurvival ERK1/2 MAPK pathway and inhibition of SAPK/JNK and p38 MAPK proapoptotic pathways <sup>68</sup>	Danieli <i>et al</i> , 2015 <sup>70</sup>
UCB-hMSCs Infused CM into rat models via tail vein	PAH	monocrotaline induced PAH rat model	Reduced ventricular pressure, the right ventricle/(left ventricle + interventricular septum) ratio and respiratory functions properly managed	Via enhanced IL-1 $\alpha$ , CCL5 and TIMP-1 levels	Lee <i>et al</i> , 2016 <sup>71</sup>
UC-hMSC Prior to administration of CM via the left renal artery, total ligation of the left ureter was done	Chronic renal disease	Rat model with unilateral ureteral obstruction	Positive treatment of renal interstitial fibrosis	Via significant reduction of MDA and ROS and enhanced activity of GSH	Liu <i>et al</i> , 2017 <sup>72</sup>

Contd...



Type of secretome/CM	Therapeutic application	Animal models or cell type	Outcome	Possible mechanisms	References
UC-hMSC Soleus muscles of both hind legs were injected with CM	Skeletal muscle atrophy	Hind limb muscle atrophy models	Significantly improved muscle mass and muscle fiber size	Via enhancing the PI3K-PKB/Akt signalling cascade	Kim <i>et al</i> 2016 <sup>73</sup>
UC-hMSC	Irradiation myocardial fibrosis	Irradiated primary HCF	Improved cell viability, reduced collagen deposition, prevented oxidative stress, increased antioxidant status and reduced pro-fibrotic cytokines	Via inhibition of the NF-κB signalling pathway	Chen <i>et al</i> , 2018 <sup>74</sup>
UC-hMSC Administered via left renal artery	Renal fibrosis	Rat models with renal interstitial fibrosis	Decreased deposition of extracellular matrix, inflammatory cell infiltration and release of inflammatory factors	Via inhibiting TLR4/NF-κB signalling pathway activation	Liu <i>et al</i> , 2018 <sup>75</sup>
Extra cellular vesicles of Adipose derived MSC Intravenous administration	Autoimmune Encephalomyelitis (AE)	Mice models with induced experimental (AE)	Reducing proliferative potency of T cells, leukocyte infiltration, and demyelination	Not reported	Jafarina <i>et al</i> , 2020 <sup>76</sup>

BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; PI3K, phosphoinositol-3-kinase; SC, stem cell; PAH, pulmonary artery hypertension; HCF, human cardiac fibroblasts; MDA, malondialdehyde; ROS, reactive oxygen species; GSH, glutathione; hMSC, human mesenchymal stromal cells; UCB, umbilical cord blood; UC, umbilical cord; AM, amniotic membrane ; PKCα, Protein Kinase C-alpha ; ERK, extracellular signal-regulated kinase; p38/MAPK, p38 mitogen-activated protein kinases; TLR4/NF-κB, Toll-like receptor 4/nuclear transcription factor-κB; PKB, Protein Kinase B

in a continuous manner. If the current limitations posed may be successfully overcome, the secretome of PPT MSCs inclusive of its EVs may become an effective therapeutic agent which could be used against a wide range of diseases/disorders.

**Financial support & sponsorship:** National Science Foundation, Sri Lanka (RG/2015/HS/01), is acknowledged for funding.

**Conflicts of Interest:** None.

## References

1. Strauer BE, Kornowski R. Stem cell therapy in perspective. *Circulation* 2003; 107 : 929-34.
2. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, *et al*. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. *J Transl Med* 2013; 11 : 196.
3. Rajput BS, Chakrabarti SK, Dongare VS, Ramirez CM, Deb KD. Human umbilical cord mesenchymal stem cells in the treatment of duchenne muscular dystrophy: Safety and feasibility study in India. *J Stem Cells* 2015; 10 : 141-56.
4. Squillaro T, Peluso G, Galderisi U. Clinical Trials with mesenchymal stem cells: An Update. *Cell Transplant* 2016; 25 : 829-48.
5. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. *Adv Cancer Res* 2008; 100 : 133-58.
6. Watanabe N, Santostefano KE, Yachnis AT, Terada N. A pathologist's perspective on induced pluripotent stem cells. *Lab Invest* 2017; 97 : 1126-32.
7. Udalamaththa VL, Jayasinghe CD, Udagama PV. Potential role of herbal remedies in stem cell therapy: Proliferation and differentiation of human mesenchymal stromal cells. *Stem Cell Res Ther* 2016; 7 : 110.
8. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal* 2011; 9 : 12.
9. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton's jelly-derived mesenchymal stem cells: Phenotypic characterization and optimizing their therapeutic potential for clinical applications. *Int J Mol Sci* 2013; 14 : 11692-712.
10. NIH US National Library of Health: Clinical trial register. Available from: <https://clinicaltrials.gov/ct2/results?term=Stem+cells&Search=Search>, accessed on April 1, 2019.
11. Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, *et al*. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. *Int J Mol Sci* 2013; 14 : 17986-8001.

12. Chou S, Chu P, Hwang W, Lodish H. Expansion of human cord blood hematopoietic stem cells for transplantation. *Cell Stem Cell* 2010; 7 : 427-8.
13. Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. *Stem Cells* 2004; 22 : 625-34.
14. Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. *Int J Mol Med* 2016; 37 : 115-25.
15. Miki T. Amnion-derived stem cells: In quest of clinical applications. *Stem Cell Res Ther* 2011; 2 : 25.
16. Wolbank S, Peterbauer A, Fahrner M, Hennerbichler S, van Griensven M, Stadler G, et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: A comparison with human mesenchymal stem cells from adipose tissue. *Tissue Eng* 2007; 13 : 1173-83.
17. Chen K, Wang D, Du WT, Han ZB, Ren H, Chi Y, et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. *Clin Immunol* 2010; 135 : 448-58.
18. Wang M, Yang Y, Yang D, Luo F, Liang W, Guo S, et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells *in vitro*. *Immunology* 2009; 126 : 220-32.
19. Tran C, Damaser MS. Stem cells as drug delivery methods: Application of stem cell secretome for regeneration. *Adv Drug Deliv Rev* 2015; 82-83 : 1-1.
20. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. *Stem Cells Int* 2016; 2016 : 6901286.
21. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. *Cell Stem Cell* 2012; 10 : 244-58.
22. Pereira T, Ivanova G, Caseiro AR, Barbosa P, Bártoło PJ, Santos JD, et al. MSCs conditioned media and umbilical cord blood plasma metabolomics and composition. *PLoS One* 2014; 9 : e113769.
23. Zisa D, Shabbir A, Suzuki G, Lee T. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. *Biochem Biophys Res Commun* 2009; 390 : 834-8.
24. Doorn J, Moll G, Le Blanc K, van Blitterswijk C, de Boer J. Therapeutic applications of mesenchymal stromal cells: Paracrine effects and potential improvements. *Tissue Eng Part B Rev* 2012; 18 : 101-15.
25. Bruno S, Grange C, Deregis MC, Calogero RA, Saviozzi S, Collino F, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. *J Am Soc Nephrol* 2009; 20 : 1053-67.
26. Lai RC, Tan SS, Yeo RW, Choo AB, Reiner AT, Su Y, et al. MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA. *J Extracell Vesicles* 2016; 5 : 29828.
27. Suh N, Subramanyam D, Lee MY. Molecular signatures of secretomes from mesenchymal stem cells/mesenchymal stemromal cells: Therapeutic benefits. *Mol Cell Toxicol* 2017; 13 : 133-41.
28. Zhang B, Wang M, Gong A, Zhang X, Wu X, Zhu Y, et al. HucMSC-exosome mediated-wnt4 signaling is required for cutaneous wound healing. *Stem Cells* 2015; 33 : 2158-68.
29. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. *Circulation* 2012; 126 : 2601-11.
30. Nargesi AA, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for renal repair. *Curr Gene Ther* 2017; 17 : 29-42.
31. Pires AO, Mendes-Pinheiro B, Teixeira FG, Anjo SI, Ribeiro-Samy S, Gomes ED, et al. Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: A proteomic analysis. *Stem Cells Dev* 2016; 25 : 1073-83.
32. Wegmeyer H, Bröske AM, Leddin M, Kuentzer K, Nisslbeck AK, Hupfeld J, et al. Mesenchymal stromal cell characteristics vary depending on their origin. *Stem Cells Dev* 2013; 22 : 2606-18.
33. Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly. *Stem Cell Res Ther* 2014; 5 : 53.
34. Kuchroo P, Dave V, Vijayan A, Viswanathan C, Ghosh D. Paracrine factors secreted by umbilical cord-derived mesenchymal stem cells induce angiogenesis *in vitro* by a VEGF-independent pathway. *Stem Cells Dev* 2015; 24 : 437-50.
35. Balasubramanian S, Thej C, Venugopal P, Priya N, Zakaria Z, Sundarraj S, et al. Higher propensity of Wharton's jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow. *Cell Biol Int* 2013; 37 : 507-15.
36. Friedman R, Betancur M, Boissel L, Tuncer H, Cetrulo C, Klingemann H. Umbilical cord mesenchymal stem cells: Adjuvants for human cell transplantation. *Biol Blood Marrow Transplant* 2007; 13 : 1477-86.
37. Pires AO, Neves-Carvalho A, Sousa N, Salgado AJ. The Secretome of Bone marrow and Wharton jelly derived mesenchymal stem cells induces differentiation and neurite outgrowth in sh-sy5y cells. *Stem Cells Int* 2014; 2014 : 438352.
38. Zhang CP, Fu XB. Therapeutic potential of stem cells in skin repair and regeneration. *Chin J Traumatol* 2008; 11 : 209-21.
39. Bartus CL, Margolis DJ. Reducing the incidence of foot ulceration and amputation in diabetes. *Curr Diab Rep* 2004; 4 : 413-8.

40. Rowan MP, Cancio LC, Elster EA, Burmeister DM, Rose LF, Natesan S, *et al*. Burn wound healing and treatment: Review and advancements. *Crit Care* 2015; *19* : 243.
41. Wirohadidjojo YW, Budiyo A, Soebono H. Regenerative effects of Wharton Jelly stem cells-conditioned medium in UVA-Irradiated human dermal fibroblasts. *Malaysian J Med Biol Res* 2016; *3* : 45-50.
42. Sánchez-A SS. Dual role for TGF- $\beta$ 1 in apoptosis. *Cytokine Growth Factor Rev* 2005; *16* : 15-34.
43. Li M, Zhao Y, Hao H, Dong L, Liu J, Han W, *et al*. Umbilical cord-derived mesenchymal stromal cell-conditioned medium exerts *in vitro* antiaging effects in human fibroblasts. *Cytotherapy* 2017; *19* : 371-83.
44. Shrestha C, Zhao L, Chen K, He H, Mo Z. Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media. *Int J Endocrinol* 2013; *2013* : 592454.
45. Padeta I, Nugroho WS, Kusindarta DL, Fibrianto YH, Budipitojo T. Mesenchymal Stem Cell conditioned Medium Promote the recovery of skin burn wound 41. *Asian J Anim Vet Adv* 2017; *132* : 141.
46. Jun EK, Zhang Q, Yoon BS, Moon JH, Lee G, Park G, *et al*. Hypoxic conditioned medium from human amniotic fluid-derived mesenchymal stem cells accelerates skin wound healing through TGF- $\beta$ /SMAD2 and PI3K/Akt pathways. *Int J Mol Sci* 2014; *15* : 605-28.
47. Kusindarta DL, Wihadmyatami H, Fibrianto YH, Nugroho WS, Susetya H, Musana DK, *et al*. Human umbilical mesenchymal stem cells conditioned medium promote primary wound healing regeneration. *Vet World* 2016; *9* : 605-10.
48. Dong L, Hao H, Liu J, Ti D, Tong C, Hou Q, *et al*. A conditioned medium of umbilical cord mesenchymal stem cells overexpressing Wnt7a promotes wound repair and regeneration of hair follicles in mice. *Stem Cells Int* 2017; *2017* : 3738071.
49. Kim ES, Jeon HB, Lim H, Shin JH, Park SJ, Jo YK, *et al*. Conditioned media from human umbilical cord blood-derived mesenchymal stem cells inhibits melanogenesis by promoting proteasomal degradation of MITF. *PLoS One* 2015; *10* : e0128078.
50. Kim YJ, Seo DH, Lee SH, Lee SH, An GH, Ahn HJ, *et al*. Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin. *Biochem Biophys Rep* 2018; *16* : 96-102.
51. Sun J, Zhang Y, Song X, Zhu J, Zhu Q. The healing effects of conditioned medium derived from mesenchymal stem cells on radiation-induced skin wounds in rats. *Cell Transplant* 2019; *28* : 105-15.
52. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): A population-based study. *Lancet Oncol* 2012; *13* : 790-801.
53. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 2018; *68* : 394-424.
54. Veeresham C. Natural products derived from plants as a source of drugs. *J Adv Pharm Technol Res* 2012; *3* : 200.
55. Elias WY, Ayoub MS, El-Malahy H, El-Kholy MM, Kayal R, Merdad KA. The effect of Wharton's Jelly mesenchymal stem cells on a squamous cell carcinoma cell line. *Arc Cancer Res* 2016; *4* : 45.
56. Hendijani F, Javanmard SH, Rafiee L, Sadeghi-Aliabadi H. Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells. *Res Pharm Sci* 2015; *10* : 134-42.
57. Hendijani F, Sadeghi-Aliabadi H, Javanmard SH. Human Wharton's Jelly mesenchymal stem cell secretome display significant antiproliferative effect on K562 leukemia cells. *Royan international twin congress, 10<sup>th</sup> congress on stem cell biology and technology*. Vol. 16. Tehran, Iran; 2014. p. 86.
58. Riedel R, Pérez AP, Maskin B, Jaime M, Parolini O, Sánchez-Margalet V, *et al*. Amniotic membrane conditioned medium promotes cell death and inhibits proliferation of hepatocarcinoma HepG2 cells. *Placenta* 2017; *51* : 114.
59. Sandra F, Sudiono J, Sidharta EA, Sunata EP, Sungkono DJ, Dirgantara Y, *et al*. Conditioned media of human umbilical cord blood mesenchymal stem cell derived secretome induced apoptosis and inhibited growth of hela cells. *Indones Bio* 2014; *6* : 57-62.
60. Mirabdollahi M, Haghjooyjavanmard S, Sadeghi-Aliabadi H. An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line. *Cell tissue bank* 2019; *20* : 423-34.
61. Zimmerlin L, Park TS, Zambidis ET, Donnenberg VS, Donnenberg AD. Mesenchymal stem cell secretome and regenerative therapy after cancer. *Biochimie* 2013; *95* : 2235-45.
62. NIH US National Library of Health: Clinical Trial Register. Available from: <https://clinicaltrials.gov/ct2/show/NCT02138331?term=NCT02138331&rank=1>. accessed on March 29, 2019.
63. NIH US National Library of Health: Clinical trial register. *Effects of ASC secretome on human osteochondral explants (ASC-OA)*. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT04223622?cond=meseenchymal+stem+cells+secretome&draw=2&rank=2>, accessed on November 21, 2020
64. NIH US National Library of Health: Clinical trial register. *Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia*. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT04753476?cond=meseenchymal+stem+cells+secretome&draw=2&rank=1>, accessed on November 21, 2020
65. Jeong SY, Kim DH, Ha J, Jin HJ, Kwon SJ, Chang JW, *et al*. Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation. *Stem Cells* 2013; *31* : 2136-48.

66. Hassan Famian M, Montazer Saheb S, Montaseri A. Conditioned Medium of Wharton's Jelly Derived Stem Cells Can Enhance the Cartilage Specific Genes Expression by Chondrocytes in Monolayer and Mass Culture Systems. *Adv Pharm Bull* 2017; 7 : 123-30.
67. Yang S, Sun HM, Yan JH, Xue H, Wu B, Dong F, *et al.* Conditioned medium from human amniotic epithelial cells may induce the differentiation of human umbilical cord blood mesenchymal stem cells into dopaminergic neuron-like cells. *J Neurosci Res* 2013; 91 : 978-86.
68. Bader A, Brodarac A, Choi YH, Kurtz A, Stamm C. Cardioprotection by cord blood mesenchymal stromal cells through activation of Akt, ERK and STAT3 signaling. *Thorac Cardiovasc Surg* 2013; 61 : OP86.
69. Lazzarini E, Balbi C, Altieri P, Pfeiffer U, Gambini E, Canepa M, *et al.* The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. *Sci Rep* 2016; 6 : 29994.
70. Danieli P, Malpasso G, Ciuffreda MC, Cervio E, Calvillo L, Copes F, *et al.* Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis. *Stem Cells Transl Med* 2015; 4 : 448-58.
71. Lee JC, Cha CI, Kim D, Choe SY. Therapeutic effects of umbilical cord blood derived mesenchymal stem cell-conditioned medium on pulmonary arterial hypertension in rats. *J Anat Soc India* 2016; 65 : 15-9.
72. Liu B, Ding FX, Liu Y, Xiong G, Lin T, He DW, *et al.* Human umbilical cord-derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction. *Nephrology (Carlton)* 2018; 23 : 728-36.
73. Kim MJ, Kim ZH, Kim SM, Choi YS. Conditioned medium derived from umbilical cord mesenchymal stem cells regenerates atrophied muscles. *Tissue Cell* 2016; 48 : 533-43.
74. Chen ZY, Hu YY, Hu XF, Cheng LX. The conditioned medium of human mesenchymal stromal cells reduces irradiation-induced damage in cardiac fibroblast cells. *J Radiat Res* 2018; 59 : 555-64.
75. Liu B, Ding F, Hu D, Zhou Y, Long C, Shen L, *et al.* Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF- $\kappa$ B signaling pathway *in vivo* and *in vitro*. *Stem Cell Res Ther* 2018; 9 : 7.
76. Jafarina M, Alsahebhosoul F, Salehi H, Eskandari N, Azimzadeh M, Mahmoodi M, *et al.* Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis. *Journal of cellular physiology*. 2020; 235 : 8779-90.
77. Angelucci S, Marchisio M, Di Giuseppe F, Pierdomenico L, Sulpizio M, Eleuterio E, *et al.* Proteome analysis of human Wharton's jelly cells during *in vitro* expansion. *Proteome Sci* 2010; 8 : 18.
78. Smith S, Neaves W, Teitelbaum S. Adult versus embryonic stem cells: Treatments. *Science* 2007; 316 : 1422-3.
79. Raff M. Adult stem cell plasticity: Fact or artifact? *Annu Rev Cell Dev Biol* 2003; 19 : 1-22.
80. Chang HK, Kim PH, Cho HM, Yum SY, Choi YJ, Son Y, *et al.* Inducible HGF-secreting human umbilical cord blood-derived MSCs produced via TALEN-mediated Genome editing promoted angiogenesis. *Mol Ther* 2016; 24 : 1644-54.
81. de Witte SFH, Merino AM, Franquesa M, Strini T, van Zoggel JAA, Korevaar SS, *et al.* Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. *Stem Cell Res Ther* 2017; 8 : 140.
82. Monguió-Tortajada M, Roura S, Gálvez-Montón C, Pujal JM, Aran G, Sanjurjo L, *et al.* Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: Implications for nanomedicine. *Theranostics* 2017; 7 : 270-84.
83. Konala VB, Mamidi MK, Bhone R, Das AK, Pochampally R, Pal R. The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration. *Cytotherapy* 2016; 18 : 13-24.

*For correspondence:* Prof Preethi Vidya Udagama, Department of Zoology & Environment Sciences, Faculty of Science, University of Colombo, Kumarathunga Munidasa Mawatha, Colombo 03, 00300, Sri Lanka  
e-mail: preethi@zoology.cmb.ac.lk